TCRX Stock Quote Price and Forecast | CNN

TCRX

TScan Therapeutics, Inc.

Key terms

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Yesterday 5:32am ET Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX) by TipRanks Apr 17 6:03am ET TScan Therapeutics 2.473M share Spot Secondary priced at $7.13 by TipRanks Apr 16 4:32pm ET TScan Therapeutics Advances in Solid and Hematological Cancer Therapy by TipRanks Apr 16 4:27pm ET TScan Therapeutics announces $125M common stock offering by TipRanks Apr 08 8:16am ET TScan Therapeutics appoints Chrysta Louis M.D CMO by TipRanks Mar 10 8:15pm ET Positive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial Position by TipRanks Mar 07 7:35am ET Strong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial Health by TipRanks Mar 07 7:07am ET Barclays Sticks to Their Buy Rating for TScan Therapeutics (TCRX) by TipRanks Mar 07 7:03am ET TScan Therapeutics price target raised to $9 from $7 at Barclays by TipRanks Mar 07 6:25am ET Buy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 Results by TipRanks Mar 06 4:13pm ET TScan Therapeutics files $300M mixed securities shelf by TipRanks Mar 06 7:04am ET TScan Therapeutics reports Q4 EPS (21c), consensus (29c) by TipRanks Feb 27 9:15am ET Buy Rating Affirmed for TScan Therapeutics Following Promising TCR-T Therapy Trial Outcomes by TipRanks Feb 27 6:28am ET Strong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment Efficacy by TipRanks Feb 27 3:28am ET TScan Therapeutics (TCRX) Receives a Buy from Barclays by TipRanks Feb 26 7:28am ET TScan Therapeutics presents Phase 1 clinical results on TSC-100, TSC-101 by TipRanks Feb 21 7:57am ET Buy Rating for TScan Therapeutics Supported by Iovance’s FDA Approval and Promising TIL Therapy Benchmark by TipRanks Feb 14 7:09am ET TScan to host virtual KOL event to discuss Phase 1 heme malignancies study by TipRanks Feb 06 7:07am ET TScan Therapeutics appoints Pinchasik as VP, Clinical Development by TipRanks

No recent press releases are available for TCRX

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.

NDZ/STAR MAX/IPx/AP

What stalled this year’s seemingly infallible stock market rally

A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.

Frederic J. Brown/AFP/Getty Images

Oil prices get short-lived boost from attack on Iran

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)

Spencer Platt/Getty Images

US regional banks are still under pressure. That’s likely to continue

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.

Frank Franklin II/AP

Trump Media stock ends session 15% higher after two very bad days